The institutional investors own 77.1% of the company’s stock pre-IPO. ObsEva is developing a lead candidate, OBE2109, which it in-licensed from Kissei Pharmaceutical Co of Japan, for the treatment of endometriosis and uterine fibroids. Endometriosis is a …
( read original story …)